The role of zinc in the pathogenesis and treatment of affective disorders;Udział cynku w patogenezie i terapii zaburzén afektywnych

Psychiatria Polska

Volumn 39, Issue 5, 2005, Pages 899-909

  Siwek, Marcin ^a   Wróbel, Andrzej ^a   Dudek, Dominika ^a   Nowak, Gabriel ^b   Ziȩba, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Depression; NMDA receptor; Zinc

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMANTADINE; AMPA RECEPTOR; CD4 ANTIGEN; CD8 ANTIGEN; CYANOCOBALAMIN; CYCLOSERINE; DIACYLGLYCEROL; GAMMA INTERFERON; GLUTAMINE; GLYCINE; HAPTOGLOBIN; INOSITOL TRISPHOSPHATE; INTERLEUKIN 1; INTERLEUKIN 6; METABOTROPIC RECEPTOR; METAPRAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; POTASSIUM ION; SODIUM ION; SPERMIDINE; SPERMINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZINC;

ANTIDEPRESSANT ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG MECHANISM; EXPERIMENTAL MODEL; HOMEOSTASIS; HUMAN; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; REGULATORY MECHANISM; SYMPTOM; TRANQUILIZING ACTIVITY; ZINC BLOOD LEVEL; ZINC DEFICIENCY;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; MOOD DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; ZINC;

EID: 28544441535     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Rzewuska M. Leczenie zaburzeń psychicznych. Warszawa: PZWL; 2003, s. 257-258.
2. Stahl SM. Podstawy psychofarmakologii depresji i choroby afektywnej dwubiegunowej. Bielsko-Biała: α: medica press; 2003, s. 23-25.
3. Skolnick P, Legutko B, Xia LI, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol. Res. 2001; 43: 411-423.
4. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 1990; 185: 1-10.
5. Pałcha A, Pilc A. Układ glutaminianergiczny - interakcja z cynkiem. W: Nowak G, red. Cynk w fizjologii oraz patofizjologii i terapii depresji. Kraków: Instytut Farmakologii PAN; 2001, s. 39-55.
6. Yamakura T, Shimoji K. Subunit - and site-specific pharmacology of the NMDA receptor channel. Progr. Neurobiol. 1999; 59: 279-298.
7. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropsychopharmacol 1998; 37: 1187-1204.
8. Chittajalu R, Braithwaite SP, Clarke VRJ, Henley JM. Kainate receptors: subunits synoptic localization and junction. Trends. Pharmacol. Sc. 1999; 20: 26-35.
9. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain functions. Science 1992; 258: 597-603.
10. Sladeczek F, Pin JP, Recasens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurons. Nature 1985; 325: 531-533.
11. Płaźnik A. Aminokwasy pobudzaja̧ce - rola w patogenezie chorób ośrodkowego układu nerwowego. W: Kostowski W, Pużyński S, red. Psychofarmakologia doświadczalna i kliniczna. Warszawa: PZWL; 1996, s. 103-112.
12. Płaźnik A. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur. J. Neuropsychopharmacol. 1994; 4: 503-523.
13. Kleinschmidt A, Bear MF, Singer W. Blockade of NMDA receptors disrupts experience dependent plasticity of kitten striate complex. Science 1987; 238: 355.
14. Danysz W, Płaźnik A. Aminokwasy pobudzaja̧ce ocean perspektyw terapeutycznych. Pol. Tyg. Lek. 1991; 46: 628.
15. Willets RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sc. 1990; 11: 432.
16. Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sc. 1994; 55: 1629-1683.
17. Seatton B. Excitatory amino acid receptor antagonists: a novel treatment for ischaemic cerebrovascular diseases. Life Sc. 1994; 55: 2115.
18. Carter AJ. Glycine antagonists: regulation of the NMDA receptor channel complex by the stryhninensensitive glycine site. Drugs Fut. 1992; 17: 595.
19. Cunningham MD, Ferkany JW, Enna S. Excitatory amino amid receptors: a galery of new targets for pharmacological intervention. Life Sc. 1993; 54: 135.
20. Harkin A, Nally R, Kelly JP, Leonard BE. Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression. J. Neural. Transm. 2000; 107: 1227-1231.
21. Nowak G, Trullas R, Laser RT, Skolnick P, Paul IA. Adaptative changes in the N-methyl-D-aspartate-receptor complex after chronic treatment with imipramine and 1-aminocyclopropranecarboxylic amid. J. Pharmacol. Exp. Ther. 1993; 265: 1380-1386.
22. Paul IA, Layer RT, Skolnick P, Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock of imipramine. Eur. J. Pharmacol. 1993; 247: 305-311.
23. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 1994; 269: 95-102.
24. Nowak G, Legutko B, Skolnick P, Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 1998; 342: 367-370.
25. Skolnick P. Antidepressant for new millennium. Eur. J. Pcharmacol. 1999; 375: 31-40.
26. Nowak G, Ossowska G, Jopek R, Papp M. Strychnine- insensivite glycine NMDA sites are altered in two stress models of depression. Pol. J. Pharmacol. 1998; 50: 365-369.
27. Kroczka B, Nowak G. Rola cynku w mechanizmie działania leków przeciwdepresyjnych. Implikacje terapeutyczne. W: Nowak G, red. Cynk w fizjologii oraz patofizjologii i terapii depresji. Krakow: Instytut Farmakologii. Polska Akademia Nauk; 2001, s. 91-109.
28. Pilc A, Klodzinska A, Nowak G. A role for glutamate in the treatment of anxiety and depression: focus on group I metabotropic glutamate (mGlu) receptors. Drugs Fut. 2002; 27(8): 753-763.
29. Schlegel-Zawadzka M. Cynk: źródła, biodostȩpność, metabolizm, preparaty cynku. W: Nowak G, red. Cynk w fizjologii oraz patofizjologii i terapii depresji. Kraków: Instytut Farmakologii. Polska Akademia Nauk; 2001, s. 7-26.
30. Solomons NW. Zinc and copper. W: Shils ME, Young VR, red. Modern nutrition in health and disease. Philadelphia: Lea & Febiger; 1988, s. 238-262.
31. Hambidge M. Human zinc deficiency. J. Nutr. 2000; 130: 1344-1349.
32. Smart TG, Xie X, Krishek BJ. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Progr. Neurobiol. 1994; 42: 393-341.
33. Danysz W, Zaja̧czkowski W, Parsons C. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 1995; 6: 455-474.
34. Danysz W, Parsons C. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 1998; 50: 597-664.
35. McLoughlin IJ, Hodge JS. Zinc in depressive disorder. Acta Psychiatr. Scand. 1990; 82: 451-453.
36. Hansen CR, Malecha M, Mackenzie TB, Kroll J. Copper and zinc deficiencies in association with depression and neurological findings. Biol. Psychiatry 1983; 18: 395-401.
37. Manser WW, Khan MA, Hazan KZ. Trace elements studies on Karachi population. Part IV: Blood copper, zinc, magnesium and lead levels in psychiatric patients with depression, mental retardation and seizure disorders. J. Pakistan Med. Assoc. 1989; 39: 269-274.
38. Narang RL, Gupta KR, Narang AP, Singh R. Levels of cooper and zinc in depression. Indian J. Physiol. Pharmacol. 1991; 35: 272-274.
39. Maes M, D'Haese PC, Scharpe S, D'Hondt P, Cosyns P, De Broe ME. Hipozincemia in depression. J. Affect. Disord. 1994; 31: 135-140.
40. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/ inflammatory response in that illness. Biol. Psychiatry 1997; 42: 269-274.
41. Maes M, De Vos N, Demeds P, Wauters A, Neels H. Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J. Affect. Disord. 1999; 56: 189-194.
42. Nowak G, Ziȩba A, Dudek D, Krośniak M, Szymaczek M, Schlegel Zawadzka M. Serum trace elements in animal models and human depression. Part 1. Zinc. Hum. Psychopharmacol. Clin. Exper. 1999; 14: 83-86.
43. Maes M, Vandewoude M, Scharpe S, De Clerck L, Stevens W, Lepoutre L, Schotte C. Anthropometric and biochemical assessment of the nutritional state in depression: evidence for lower visceral protein plasma levels in depression. J. Affect. Disord. 1991; 23: 25-33.
44. Schlegel-Zawadzka M, Ziȩba A, Dudek D: Zwyczaje żywieniowe a zawartość cynku we krwi u pacjentów w chorobach afektywnych. Badanie wstȩpne. Żywienie Człow. Metabol. 2000; supl. XXVII: 216-219.
45. Mulle N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Progr. Neuropsychopharmacol. Biol. Psychiatry 1993; 17: 713-730.
46. Maes M. The immune pathophysiology of major depression. W: Honig A, van Praag HM. Depression: neurobiological, psychopathological and therapeutic advances. Chichester: John Wiley; 1997, s. 197-215.
47. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res. 1996; 64: 161-167.
48. Perini GI, Zara M, Carraro C, Tosin C, Gava F, Santucci MG, Valverde S, Defranchis G. Psychoimmunoendocrine effects of panic disorder. Hum. Psychopharmacol. 1995; 10: 461-465.
49. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol. 1995; 41: 534-538.
50. Joyce PR, Hawes CR, Mulder RT, Sellman JD, Wilson DA, Boswell DR. Elevated levels of acute phase plasma proteins in major depression. Biol. Psychiatry 1992; 32: 1035-1041.
51. Maes M, Scharpe S, van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E. Higher a lantitripsin, haptoglobin, coeruloplasmin, and lower retinal binding protein plasma levels during depression: Further evidence for existence of an inflammatory response during that illness. J. Affect. Disord. 1992; 24: 183-192.
52. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 1994; 30: 283-288.
53. Maes M, Bosmans E, De Joungh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
54. Nowak G, Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment. Part I. Zinc. Biol. Trace Elem. Res. 1999; 67: 85-92.
55. Kroczka B, Ziȩba A, Dudek D, Pilc A, Nowak G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol. J. Pharmacol. 2000; 52: 403-406.
56. Szewczyk B, Branski P, Wieronska JM, Palucha A, Pilc A, Nowak G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol. J. Pharmacol. 2002; 54: 681-685.
57. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull. 2003; 61: 159-164.
58. Nowak G, Siwek M, Dudek D, Ziȩba A, Pilc A. Effect of zinc supplementation on antidepressant therapy In unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. 2003; 55(6): 1143-1147.